跳转至内容
Merck

840465P

Avanti

18:0 PG

Avanti Research - A Croda Brand

别名:

1,2-二十八烷酰基-sn-甘油-3-磷酸-(1′rac甘油)(钠盐); DSPG; PG(18:0/18:0); 110649

登录查看公司和协议定价


About This Item

经验公式(希尔记法):
C42H82O10PNa
分子量:
801.06
分類程式碼代碼:
51191904
NACRES:
NA.25

描述

1,2-distearoyl-sn-glycero-3-phospho-(1′-rac-glycerol) (sodium salt)

化驗

>99% (TLC)

形狀

powder

包裝

pkg of 1 × 1 g (840465P-1g)
pkg of 1 × 200 mg (840465P-200mg)
pkg of 1 × 25 mg (840465P-25mg)

製造商/商標名

Avanti Research - A Croda Brand

脂質類型

phospholipids
cardiolipins

儲存溫度

−20°C

InChI

1S/C42H83O10P.Na/c1-3-5-7-9-11-13-15-17-19-21-23-25-27-29-31-33-41(45)49-37-40(38-51-53(47,48)50-36-39(44)35-43)52-42(46)34-32-30-28-26-24-22-20-18-16-14-12-10-8-6-4-2;/h39-40,43-44H,3-38H2,1-2H3,(H,47,48);/q;+1/p-1/t39?,40-;/m1./s1

InChI 密鑰

YNQYZBDRJZVSJE-QTOMIGAPSA-M

包裝

20 mL透明玻璃螺旋盖小瓶(840465P-1g)
5 mL琥珀色玻璃螺旋盖小瓶(840465P-200mg)
5 mL琥珀色玻璃螺旋盖小瓶(840465P-25mg)

法律資訊

Avanti Research is a trademark of Avanti Polar Lipids, LLC

儲存類別代碼

11 - Combustible Solids

水污染物質分類(WGK)

WGK 3

閃點(°F)

Not applicable

閃點(°C)

Not applicable


分析证书(COA)

输入产品批号来搜索 分析证书(COA) 。批号可以在产品标签上"批“ (Lot或Batch)字后找到。

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

Naomi Benne et al.
Journal of controlled release : official journal of the Controlled Release Society, 318, 246-255 (2019-12-10)
Regulatory T cells (Tregs) are vital for maintaining a balanced immune response and their dysfunction is often associated with auto-immune disorders. We have previously shown that antigen-loaded anionic liposomes composed of phosphatidylcholine (PC) and phosphatidylglycerol (PG) and cholesterol can induce
Margaret W Ndinguri et al.
Journal of drug delivery, 2012, 592602-592602 (2012-12-06)
Cancer treatment by chemotherapy is typically accompanied by deleterious side effects, attributed to the toxic action of chemotherapeutics on proliferating cells from nontumor tissues. The cell surface proteoglycan CD44 has been recognized as a cancer stem cell marker. The present
Noel Vera-González et al.
Journal of biomedical materials research. Part A, 108(11), 2263-2276 (2020-05-05)
Fungal infections can cause significant patient morbidity and mortality. Nanoparticle therapeutics have the potential to improve treatment of these infections. Here we report the development of liposomal nanoparticles incorporating anidulafungin, a potent antifungal, with the goal of increasing its solubility
Parvin Zamani et al.
Life sciences, 252, 117646-117646 (2020-04-10)
Myeloid-derived suppressor cells (MDSCs) are immunosuppressive cells causing resistance to immunotherapies in cancer tumors. In the current study, various immunogenic and therapeutic features of the combination therapies with non-liposomal Doxorubicin (Dox) and the E75 immunogenic peptide (Pep), derived from the
Kevin A Carter et al.
Nature communications, 5, 3546-3546 (2014-04-05)
The delivery of therapeutic compounds to target tissues is a central challenge in treating disease. Externally controlled drug release systems hold potential to selectively enhance localized delivery. Here we describe liposomes doped with porphyrin-phospholipid that are permeabilized directly by near-infrared

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系技术服务部门